MDT-AP-0838
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 107.03999999999999
- os_event
- true
- age_years
- 8
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.783518418
- umap2_2d
- 7.104441523
- umap1_3d
- 3.298907474
- umap2_3d
- -0.590890663
- umap3_3d
- -4.261317285
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.150
- PROTEIN_SECRETION+0.110
- HEME_METABOLISM+0.100
- ADIPOGENESIS+0.070
- APICAL_JUNCTION+0.060
- PI3K_AKT_MTOR_SIGNALING+0.060
- MYOGENESIS+0.040
- TGF_BETA_SIGNALING+0.040
- XENOBIOTIC_METABOLISM+0.040
- INTERFERON_ALPHA_RESPONSE+0.030
Top 10 suppressed
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V1-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- ANDROGEN_RESPONSE-0.390
- ANGIOGENESIS-0.370
- UV_RESPONSE_DN-0.340
- MTORC1_SIGNALING-0.330
- ALLOGRAFT_REJECTION-0.320
- KRAS_SIGNALING_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0808 | Med | Medulloblastoma | 0.906 |
| 2 | MDT-AP-0734 | Med | Medulloblastoma | 0.896 |
| 3 | MDT-AP-0381 | Med | Medulloblastoma | 0.874 |
| 4 | MDT-AP-0364 | Med | Medulloblastoma | 0.868 |
| 5 | MDT-AP-0757 | Med | Medulloblastoma | 0.860 |
| 6 | MDT-AP-0343 | Med | Medulloblastoma | 0.850 |
| 7 | MDT-AP-1354 | Med | Medulloblastoma | 0.849 |
| 8 | MDT-AP-0830 | Med | Medulloblastoma | 0.847 |
| 9 | MDT-AP-0405 | Med | Medulloblastoma | 0.835 |
| 10 | MDT-AP-0402 | Med | Medulloblastoma | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.030 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |